Use of adjunctive aerosolized antimicrobial therapy in the treatment of pseudomonas aeruginosa and acinetobacter baumannii ventilator-associated pneumonia

Respiratory Care

Volumn 57, Issue 8, 2012, Pages 1226-1233

  Arnold, Heather Marin ^a   Sawyer, Amber M ^b   Kollef, Marin H ^a  

^a BARNES JEWISH HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS HOSPITAL   (United States)

Author keywords

Acinetobacter baumannii; Aerosolized antibiotics; Pseudomonas aeruginosa; Ventilator associated pneumonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFEPIME; COLISTIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; APACHE; BRONCHOALVEOLAR LAVAGE; COLISTIN; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84859966602     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01556     Document Type: Article

References (19)

1. Restrepo MI, Anzueto A, Arroliga AC, Afessa B, Atkinson MJ, Ho NJ, et al. Economic burden of ventilator-associated pneumonia based on total resource utilization. Infect Control Hosp Epidemiol 2010; 31(5):509-515.
2. Safdar N, Dezfulian C, Collard H, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33(10):2184-2193.
3. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157(2):531-539.
4. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Alexandria, VA: Infectious Diseases Society of America; 2004. http://www. idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/ Current_Topics_and_Issues/Antimicrobial_Resistance/10x20/ Images/Bad%20Bugs%20no%20Drugs.pdf. Accessed May 22, 2012.
5. Infectious Diseases Society of America. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50(8):1081-1083.
6. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010;65(12):2645-2649.
7. Czosnowski QA, Wood GC, Magnotti LJ, Croce MA, Swanson JM, Boucher BA, Fabian TC. Adjunctive aersolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009; 29(9):1054-1060.
8. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilatorassociated pneumonia: a matched case-control study. Clin Infect Dis 2010;51(11):1238-1244.
9. Pingleton SK, Fagon JY, Leeper KV Jr. Patient selection for clinical investigation of ventilator-associated pneumonia. Criteria for evaluating diagnostic techniques. Chest 1992;102(5 Suppl 1): 553S-556S.
10. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143(5):1121-1129.
11. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008;102(3):407-412.
12. Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 2009;13(6):R200.
13. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008;36(7):2008-2013.
14. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ; the Nebulized Antibiotics Study Group. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;184(1):106-115.
15. Wood GC, Underwood EL, Croce MA, Swanson JM, Fabian TC. Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann Pharmacother 2010;44(10):1665-1668.
16. Johnson M, Reichley R, Hoppe-Bauer J, Micek ST, Kollef MH. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med 2011;39(8):1859-1865.
17. Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J. Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr Opin Infect Dis 2009;22(2):154-158.
18. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122(1):262-268.
19. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2011;(3):CD001021.